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Heme Oxygenase-1 and 2 Common 
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Jorge Millán-Pascual6, María Díaz-Sánchez4,5, Patricia Calleja4,5, Diana Pisa7, Laura Turpín-
Fenoll 6, Hortensia Alonso-Navarro6,8,9, Pau Pastor3,10,11,12, Sara Ortega-Cubero3,10,11, 
Lucía Ayuso-Peralta8, Dolores Torrecillas8, Esteban García-Albea8, José Francisco Plaza-Nieto9 
& Félix Javier Jiménez-Jiménez8,9
Several neurochemical, neuropathological, and experimental data suggest a possible role of oxidative 
stress in the ethiopathogenesis of multiple sclerosis(MS). Heme-oxygenases(HMOX) are an important 
defensive mechanism against oxidative stress, and HMOX1 is overexpressed in the brain and spinal 
cord of MS patients and in experimental autoimmune encephalomyelitis(EAE). We analyzed whether 
common polymorphisms affecting the HMOX1 and HMOX2 genes are related with the risk to develop 
MS. We analyzed the distribution of genotypes and allelic frequencies of the HMOX1 rs2071746, HMOX1 
rs2071747, HMOX2 rs2270363, and HMOX2 rs1051308 SNPs, as well as the presence of Copy number 
variations(CNVs) of these genes in 292 subjects MS and 533 healthy controls, using TaqMan assays. The 
frequencies of HMOX2 rs1051308AA genotype and HMOX2 rs1051308A and HMOX1 rs2071746A alleles 
were higher in MS patients than in controls, although only that of the SNP HMOX2 rs1051308 in men 
remained as significant after correction for multiple comparisons. None of the studied polymorphisms 
was related to the age at disease onset or with the MS phenotype. The present study suggests a weak 
association between HMOX2 rs1051308 polymorphism and the risk to develop MS in Spanish Caucasian 
men and a trend towards association between the HMOX1 rs2071746A and MS risk.
Despite Genome-wide association studies (GWAS) in MS confirmed more than 100 loci with genome-wide sig-
nificance (most of them with modest odds-ratio-OR), only HLA (in particular the HLA-DRB1*15:01 haplotype) 
showed a strong association with the risk for MS1. Many studies of oxidative stress markers in the brain, spinal 
cord, and cerebrospinal fluid of patients diagnosed with MS, and in the experimental model of autoimmune 
encephalomyelitis (EAE), suggested a possible role of oxidative stress and lipid peroxidation in the pathogenesis 
of MS (revised in1).
Heme oxygenase is an essential enzyme in heme catabolism by cleaving heme to biliverdin, which is sub-
sequently converted to bilirubin and carbon monoxide (CO). Heme oxygenase occurs as 2 main isozymes, an 
inducible heme oxygenase-1 (HMOX1), and a constitutive heme oxygenase-2 (HMOX2), which are encoded 
by the genes designated, respectively, as HMOX1, HO-1 or HSP32 (gene identity 3162, chromosome 22q13.1) 
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and HMOX2 or HO-2 (gene identity 3163, chromosome 16p13.3). Several recent studies have shown association 
between certain single nucleotide polymorphisms (SNPs) in the HMOX12–5 and HMOX24,6 genes and the risk for 
Parkinson’s disease (PD)2,4,6, essential tremor (ET)5, and restless legs syndrome7.
HMOX1 expression have been found up-regulated both in the brain8–11 and in the spinal cord11 of experimen-
tal models of EAE, and in the inflammatory lesions in the brain of patients diagnosed with MS11,12 and acute dis-
seminated leucoencephalomyelitis11. Fagone et al.13 showed decreased expression of HMOX1 in peripheral blood 
mononuclear cells of MS patients, the decrease being more evident during exacerbations of the disease. A recent 
study with DNA microarray analysis in leukocytes from the cerebrospinal fluid of MS patients showed decreased 
expression of the HMOX1 gene14. It has been reported that EAE induced in HMOX1 knockout mice is more 
severe than in HMOX1 wild-type mice in terms of Central Nervous System demyelination, paralysis, and mor-
tality, being these effects partially reversed by administration cobalt protoporphyrin IX (inductor of HMOX1) or 
CO15. Induction of HMOX1 by haemin can inhibit EAE as well16. In addition, the prolonged prophylactic admin-
istration of CO-releasing molecules (CORMs) partially improves clinical and histopathological features of EAE 
in rodent models, and it has been proposed as potentially useful in the treatment of MS17,18.
HMOX1 acts as a heat shock protein, and is induced by oxidative stress. The possible role of oxidative stress in 
the pathogenesis of MS1, together with the previously mentioned data regarding HMOX1 in MS and in the EAE 
model makes that analysis of a possible relationship between HMOX polymorphisms and MS risk could seem 
reasonable, despite HMOX polymorphisms have not been mentioned among the possible susceptibility genes in 
GWAS. Recently, Zborníková et al.19 showed lack of association between HMOX1 gene promoter (GT)n polymor-
phism and progression of MS in a sample of 338 MS patients.
With the aim of investigate a possible association between HMOX1 and HMOX2 polymorphisms and the risk 
of developing MS, we genotyped HMOX1 and HMOX2 SNPs in a large group of Caucasian Spanish MS patients 
and controls.
Results
The frequencies of the rs2071746, rs2071747, rs2270363, and rs1051308 genotypes and allelic variants, both in MS 
patient and control groups, were in Hardy-Weinberg’s equilibrium (Table 1). With a single exception, all partici-
pants carried two copies of the HMOX1 and HMOX2 genes; only one control individual carried a single copy of 
the HMOX1 gene; and hence CNVs were not further considered as major putative risk factors. The frequencies 
of HMOX2 rs1051308AA genotype and HMOX2 rs1051308A and HMOX1 rs2071746A alleles were significantly 
higher in MS patients than in controls (Table 2). HMOX2 rs1051308AA genotype and HMOX2 rs1051308A allele 
were overrepresented in males, and HMOX1 rs2071746A allele in the female gender (Table 3). These differences 
did not remain significant after multiple comparison analysis applying the false discovery rate correction, with 
the exception of the SNP HMOX2 rs1051308 in men (Table 2). The frequencies of rs2071747 and rs2270363 did 
not differ significantly between MS patient and control groups.
Mean ± SD age at onset of MS was similar between MS patients carrying the genotypes rs2071746AA, 
rs2071746AT, and rs2071746TT (33.0 ± 12.5, 32.4 ± 10.2, and 32.4 ± 8.9 years, respectively); genotypes 
rs2071747GG and rs2071747GC (32.8 ± 11.0 and 30.3 ± 6.2 years, respectively); genotypes rs2270363GG, 
rs2270363GA, and rs2270363AA (32.7 ± 11.9, 33.1 ± 9.8, and 29.8 ± 9.1 years, respectively); and genotypes 
rs1051308AA, rs1051308AG, and rs1051308AA (32.5 ± 11.6, 33.4 ± 9.9, and 28.6 ± 8.2 years, respectively).
The distribution of the HMOX1 and HMOX2 SNPs genotypes and allelic frequencies was similar for those MS 
patients with “relapsing-remitting”, “primary progressive”, and “secondary progressive” phenotypes of MS, and 
when compared each type with controls (Table 3).
Discussion
Data from the present case-control association study suggest a weak association between the allelic variants 
HMOX2 rs1051308A and HMOX1 rs2071746A with the risk for MS (although only HMOX2 rs1051308A was 
finally associated after multiple comparison analysis), while the other 2 studied SNPs in the HMOX gene were not 
associated with a modification of MS risk. However, none of the studied SNPs were related with the age at onset 
of MS or with the specific risk for any of the MS phenotypes.
We have previously reported association between HMOX1 rs2071746 variant and the risk for PD, ET, and 
restless legs syndrome4,5,7 suggesting a possible link between these diseases. However, there are no clues on puta-
tive biological mechanisms underlying the association found. The rs2071746 SNP is located in the 5′ area, about 
500 bp before the coding area, and therefore the most likely mechanism would be related to gene expression. The 
area where the SNP is located has several transcription factor binding sites. One of these, designated as CUTL1 
[T00100] is present in the wild-type sequence, but is disappears in the mutated sequence. The disruption of this 
transcription factor binding site may underlie differences in terms of gene expression. It has been suggested 
that both rs2071746 SNP and the HMOX1 gene promoter (GT)n polymorphism could be related with HMOX1 
enzyme activity20.
In the brain, the HMOX pathway (in particular HMOX1) is a very important defensive mechanism against 
oxidative stress, mainly through the degradation of heme to biliverdin, free iron, and CO. Moreover, an 
up-regulation of HMOX1 expression has been found in the brains of patients with PD, Alzheimer’s disease, and 
multiple sclerosis.21,22
A limitation of the current study is that, while 3 of the SNPs studies had a high statistical power, the other one 
(rs2071747), had not. However, it must be taken in consideration that rs2071747 is an allele with a very low minor 
frequency (MAF) in healthy Europeans (0.045 in the current study and 0.060 in the 1000 genomes database), 
and it is very rare in other human populations, with MAF ranging from 0.020 to 0.050 (http://browser.1000ge-
nomes.org/Homo_sapiens/Variation/Population? db= core;r= 22:35776685-3577785;v= rs2071747;vdb= varia-
tion;vf= 1641286). Therefore, the minimum sample size to obtain a reliable statistical power for such SNP with a 
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RR value = 1.5 (p = 0.05), is estimated to be 1900 case-control pairs. Moreover, it the significant findings in this 
study are related to another SNPs that have a relatively high statistical power.
Other potential limitation is the fact that the cohort study included MS patients with different degrees of 
severity. This does not allow to investigate the influence of HMOX genotypes on disability or severity of the 
GENOTYPES
MS PATIENTS 
(N = 292, 584 alleles)
CONTROLS (N = 533, 
1066 alleles)
OR (95% CI), P; Pc; 
NPV (95% CI)
HMOX1 rs2071746 A/A 102 (34.9; 29.5–40.4) 154 (28.9; 25.0–32.7) 1.32 (0.96–1.81); 0.073; 0.292; 0.67 (0.64–0.69)
A/T 139 (47.6; 41.9–53.3) 256 (48.0; 43.8–52.3) 0.98 (0.73–1.32); 0.907; 0.973; 0.64 (0.61–0.68)
T/T 51 (17.5; 13.1–21.8) 122 (22.9; 19.3–26.5) 0.71 (0.49–1.04); 0.067; 0.292; 0.63 (0.61–0.65)
Null/A 0 (—) 1 (0.2; 0.-2-0.6) 0.00 (0.00–31.69); 0.459; 0.667; 0.65 (0.65-0.65)
Null/T 0 (—) 0 (—) —
HMOX1 rs2071747 G/G 266 (91.1; 87.8–94.4) 485 (91.0; 88.6–93.4) 1.01 (0.60–1.72); 0.961; 0.973; 0.65 (0.53–0.75)
G/C 25 (8.6; 5.4–11.8) 46 (8.6; 6.2–11.0) 0.99 (0.58–1.70); 0.973; 0.973; 0.65 (0.64–0.66)
C/C 1 (0.3; 0.-3-1.0) 1 (0.2; 0.-2-0.6) 1.82 (0.05–67.02); 0.666; 0.819; 0.65 (0.65–0.65)
Null/G 0 (—) 1 (0.2; 0.-2-0.6) 0.00 (0.00–31.69); 0.459; 0.667; 0.65 (0.65–0.65)
Null/C 0 (—) 0 (—) —
HMOX2 rs2270363 G/G 127 (43.5; 37.8–49.2) 253 (47.5; 43.2–51.7) 0.85 (0.63–1.15); 0.274; 0.667; 0.63 (0.60–0.66)
G/A 130 (44.5; 38.8–50.2) 227 (42.6; 38.4–46.8) 1.08 (0.80–1.46); 0.593; 0.790; 0.65 (0.62–0.68)
A/A 35 (12.0; 8.3–15.7) 52 (9.8; 7.2–12.3) 1.26 (0.78–2.03); 0.319; 0.667; 0.65 (0.64–0.66)
Null/G 0 (—) 1 (0.2; 0.-2-0.6) 0.00 (0.00–31.69); 0.459; 0.667; 0.65 (0.65–0.65)
Null/A 0 (—) 0 (—) —
HMOX 2 rs1051308 A/A 147 (50.3; 44.6–56.1) 227 (42.6; 38.4–46.8) 1.37 (01.02–0.84); 0.033; 0.292; 0.68 (0.65–0.71)
A/G 120 (41.1; 35.5–46.7) 236 (44.3; 40.1–48.5) 0.88 (0.65–1.19); 0.378; 0.667; 0.63 (0.60–0.66)
G/G 25 (8.6; 5.4–11.8) 69 (12.9; 10.1–15.8) 0.63 (0.68–1.04); 0.058; 0.292; 0.64 (0.62–0.65)
Null/A 0 (—) 0 (—) —
Null/G 0 (—) 1 (0.2; 0.-2-0.6) 0.00 (0.00–31.69); 0.459; 0.667; 0.65 (0.65–0.65)
ALLELES
HMOX1 rs2071746 A 343 (58.7; 54.7–62.7) 565 (53.0; 50.0–56.0) 1.26 (1.02–1.56); 0.025; 0.063; 0.68 (0.65–0.70)
T 241 (41.3; 37.3–45.3) 501 (47.0; 44.0–50.0) 0.79 (0.64–0.98); 0.025; 0.063; 0.62 (0.60–0.64)
HMOX1 rs2071747 G 557 (95.4; 93.7–97.1) 1017 (95.5; 94.2–96.7) 0.97 (0.59–1.62); 0.914; 0.914; 0.64 (0.52–0.74)
C 27 (4.6; 2.9–6.3) 48 (4.5; 3.3–5.8) 1.03 (0.62–1.71); 0.914; 0.914; 0.65 (0.64–0.65)
HMOX2 rs2270363 G 384 (65.8; 61.9–69.6) 734 (68.9; 66.1–71.7) 0.87 (0.70–1.08); 0.188; 0.313; 0.62 (0.59–0.66)
A 200 (34.2; 30.4–38.1) 331 (31.1; 28.3–33.9) 1.16 (0.93–1.44); 0.188; 0.313; 0.66 (0.64–0.67)
HMOX 2 rs1051308 A
414 (70.9; 67.2–74.6) 690 (64.8; 61.9–67.7) 1.32 (1.06–0.66); 0.012; 0.060; 0.69 (0.65–0.72)
G 170 (29.1; 25.4–32.8) 375 (35.2; 32.3–38.1) 0.76 (0.60–0.95); 0.012; 0.060; 0.63 (0.61–0.64)
Null HMOX1 0 (—) 1 (0.1; 0.-1-0.3) 0.00 (0.00–31.61); 0.459; 0.573; 0.65 (0.65–0.65)
Null HMOX 2 0 (—) 1 (0.1; 0.-1-0.3) 0.00 (0.00–31.61); 0.459; 0.573; 0.65 (0.65–0.65)
Table 1.  HMOX genotypes and allelic variants of patients with MS and healthy volunteers. The values in 
each cell represent: number (percentage; 95% confidence intervals). Pc probability after correction for multiple 
comparisons. NPV: negative predictive value.
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GENOTYPES
MS WOMEN 
(N = 201, 402 
ALLELES)
CONTROL 
WOMEN 
(N = 367, 734 
ALLELES)
INTERGROUP 
COMPARISON 
OR (95% CI), P; 
PC ; NPV (95% 
CI)
MS MEN 
(N = 91, 182 
ALLELES)
CONTROL 
MEN (N = 165, 
332 ALLELES)
INTERGROUP 
COMPARISON 
OR (95% CI) P; 
PC; NPV (95% 
CI)
HMOX1 rs2071746 A/A 69 (34.3; 27.8–40.9)
101 (27.5; 
23.0–32.1)
1.38 (0.93–2.03); 
0.091; 0.396; 0.67 
(0.640.70)
33 (36.3; 
26.4–46.1)
53 (32.1; 
25.0–39.2)
1.20 (0.68–2.13); 
0.503; 0.721; 0.66 
(0.62–0.70)
A/T 98 (48.8; 41.8–55.7)
182 (49.6; 
44.5–54.7)
0.97 (0.68–1.39); 
0.849; 0.858; 0.64 
(0.60–0.68)
41 (45.1; 
34.8–55.3)
74 (44.8; 
37.3–52.4)
1.01 (0.58–1.74); 
0.975; 0.975; 0.65 
(0.59–0.70)
T/T 34 (16.9; 11.7–22.1)
84 (22.9; 
18.6–27.2)
0.69 (0.43–1.09); 
0.094; 0.396; (0.63 
(0.61–0.65)
17 (18.7; 
10.7–26.7)
38 (23.0; 
16.6–29.5)
0.77 (0.39–1.52); 
0.418; 0.721; 0.63 
(0.60–0.67)
HMOX1 rs2071747 G/G 181 (90.0; 85.9–94.2)
334 (91.0; 
88.1–93.9)
0.89 (0.48–1.67); 
0.708; 0.858; 0.62 
(0.49–0.75)
85 (93.4; 
88.3–98.5)
151 (91.5; 
87.3–95.8)
1.31 (0.45–4.00); 
0.590; 0.721; 0.70 
(0.47–0.87)
G/C 19 (9.5; 5.4–13.5) 32 (8.7; 5.8–11.6)
1.09 (0.58–2.06); 
0.770; 0.858; 0.65 
(0.64–0.66)
6 (6.6; 1.5–11.7) 14 (8.5; 4.2–12.7)
0.76 (0.25–2.22); 
0.590; 0.721; 0.64 
(0.63–0.66)
C/C 1 (0.5; 0.-5-1.5) 1 (0.3; 0.3–0.8)
1.83 (0.05–67.24); 
0.665; 0.858; 0.65 
(0.65–0.65)
0 (0.0; 0.0-0.0) 0 (0.0; 0.0-0.0) —
HMOX2 rs2270363 G/G 85 (42.3; 35.5–49.1)
175 (47.7; 
42.6–52.8)
0.80 (0.56–1.15); 
0.218; 0.654; 0.62 
(0.59–0.66)
42 (46.2; 
35.9–56.4)
78 (47.3; 
39.7–54.9)
0.96 (0.55–1.65); 
0.864; 0.950; 0.64 
(0.58–0.70)
G/A 87 (43.3; 36.4–50.1)
156 (42.5; 
37.4–47.6)
1.03 (0.72–1.48); 
0.858; 0.858; 0.65 
(0.61–0.69)
43 (47.3; 
37.0–57.5)
71 (43.0; 
35.5–50.6)
1.19 (0.69–2.05); 
0.516; 0.721; 0.66 
(0.61–0.72)
A/A 29 (14.4; 9.6–19.3)
36 (9.8; 
6.8–12.9)
1.55 (0.89–2.70); 
0.099; 0.396; 0.66 
(0.64–0.67)
6 (6.6; 1.5–11.7) 16 (9.7; 5.2–14.2)
0.66 (0.22–1.88); 
0.397; 0.721; 0.64 
(0.62–0.66)
HMOX 2 rs1051308 A/A 94 (46.8; 39.9–53.7)
158 (43.1; 
38.0–48.1)
1.16 (0.81–1.67); 
0.395; 0.858; 0.66 
(0.63–0.70)
53 (58.2; 
48.1–68.4)
69 (41.8; 
34.3–49.3)
1.94 (0.12–3.37); 
0.012; 0.072; 0.72 
(0.66–0.77)
A/G 85 (42.3; 35.5–49.1)
161 (43.9; 
38.8–48.9)
0.94 (0.65–1.35); 
0.716; 0.858; 0.64 
(0.60–0.68)
35 (38.5; 
28.5–48.5)
75 (45.5; 
37.9–53.1)
0.75 (0.43–1.31); 
0.280; 0.721; 0.62 
(0.56–0.67)
G/G 22 (10.9; 6.6–15.3)
48 (13.1; 
9.6–16.5)
0.82 (0.46–1.44); 
0.460; 0.858; 0.64 
(0.63–0.66)
3 (3.3; 0.–4–7.0) 21 (12.7; 7.6–17.8)
0.23 (0.06–0.86); 
0.013; 0.072; 0.62 
(0.61–0.64)
ALLELES
HMOX1 rs2071746 A 236 (58.7; 53.9–63.5)
384 (52.3; 
48.7–55.9)
1.30 (1.01–1.67); 
0.039; 0.156; 0.68 
(0.65–0.71)
107 (58.8; 
51.6–65.9)
180 (54.5; 
49.2–59.9)
1.19 (0.81–1.74); 
0.355; 0.710; 0.67 
(0.62–0.72)
T 166 (41.3; 36.5–46.1)
350 (47.7; 
44.1–51.3)
0.77 (0.60–0.99); 
0.039; 0.156; 0.62 
(0.59–0.65)
75 (41.2; 
34.1–48.4)
150 (45.5; 
40.1–50.8)
0.84 (0.57–1.23); 
0.355; 0.710; 0.63 
(0.59–0.67)
HMOX1 rs2071747 G 381 (94.8; 92.6–97.0)
700 (95.4; 
93.8–96.9)
0.88 (0.49–1.60); 
0.657; 0.657; 0.62 
(0.48–0.74)
176 (96.7; 
94.1–99.3)
316 (95.8; 
93.6–97.9)
1.30 (0.46–3.86); 
0.597; 0.796; 0.70 
(0.46–0.87)
C 21 (5.2; 3.0–7.4) 34 (4.6; 3.1–6.2)
1.14 (0.63–2.05); 
0.657; 0.657; 0.65 
(0.64–0.66)
6 (3.3; 0.7–5.9) 14 (4.2; 2.1–6.4)
0.77 (0.26–2.19); 
0.597; 0.796; 0.64 
(0.64–0.65)
HMOX2 rs2270363 G 257 (63.9; 59.2–68.6)
506 (68.9; 
65.6–72.3)
0.80 (0.61–1.04); 
0.086; 0.172; 0.61 
(0.57–0.65)
127 (69.8; 
63.1–76.5)
227 (68.8; 
63.8–73.8)
1.05 (0.69–1.58); 
0.816; 0.816; 0.65 
(0.59–0.72)
A 145 (36.1; 31.4–40.8)
228 (31.1; 
27.7–34.4)
1.25 (0.96–1.63); 
0.086; 0.172; 0.66 
(0.64–0.68)
55 (30.2; 
23.5–36.9)
103 (31.2; 
26.2–36.2)
0.95 (0.63–1.44); 
0.816; 0.816; 0.64 
(0.61–0.67)
HMOX 2 rs1051308 A 273 (67.9; 63.3–72.5)
477 (65.0; 
61.5–68.4)
1.14 (0.87–1.49); 
0.320; 0.427; 0.67 
(0.63–0.71)
141 (77.5; 
71.4–83.5)
213 (64.5; 
59.4–69.7)
1.89 (1.22–2.92); 
0.002; 0.008; 0.74 
(0.68–0.80)
G 129 (32.1; 27.5–36.7)
257 (35.0; 
31.6–38.5)
0.88 (0.67–1.15); 
0.320; 0.427; 0.64 
(0.62–0.66)
41 (22.5; 
16.5–28.6)
117 (35.5; 
30.3–40.6)
0.53 (0.34–0.82); 
0.002; 0.008; 0.60 
(0.58–0.63)
Table 2.  HMOX genotypes and allelic variants of patients with MS and healthy volunteers distributed by 
gender. The values in each cell represent: number (percentage; 95% confidence intervals). Pc probability after 
correction for multiple comparisons. NPV: negative predictive value. Control individuals with null genotypes 
were excluded because copy number variations were not relevant as putative risk factors (see above).
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disease. The optimum design for this aim should be a prospective one, including the genotyping of patients with 
a recent diagnosis of MS and the re-examination of the same cohort of MS patients after a similar long-term 
follow-up period in order to establish the final evolutive type.
Although the results of the present study should be taken with caution because the previously discussed lim-
itations, and deserve a confirmation with further replication studies in other populations, they suggest a slightly 
increased risk for MS in Spanish Caucasian men carrying the HMOX2 rs1051308A allele variant, and a trend 
towards association between the HMOX1 rs2071746A and MS risk.
Methods
Patients and controls. The study included a total number of 292 MS individuals fulfilling the McDonald’s 
criteria for definite MS23 (91 men, 201 women, mean age 44.1 ± 11.4 years, mean age at onset 32.8 ± 10.9 years; 
mean expanded disability score scale-EDSS = 3.26 ± 2.39; 157 relapsing-remitting, 93 secondary progressive, and 
42 primary progressive MS), who had no other previous neurological diseases, and 533 gender-matched con-
trol subjects. Two-hundred and seventy five controls were recruited from the Clínica Universidad de Navarra 
(Pamplona, Spain) and 258 controls were recruited from the Infanta Cristina University Hospital, (Badajoz, 
Spain). All consecutive patients diagnosed by consultant neurologists were requested to participate and all of 
them agreed to do so.
Ethical aspects. All the participants included in the study gave their written informed consent after full 
explanation of the procedure. The study, which was conducted in accordance with the principles of the Helsinki 
declaration of 1975, was approved by the Ethics Committees of Clinical Investigation of the University Hospital 
“Príncipe de Asturias” (University of Alcalá, Alcalá de Henares, Madrid, Spain), the Infanta Cristina University 
Hospital (Badajoz, Spain), and Clínica Universitaria de Navarra (Pamplona, Spain). Most of the patients recruited 
had participated in other previous studies of genetic association with MS risk1,24–30.
Genotyping. Two single nucleotide polymorphisms in the HMOX1 gene and another two polymorphisms in 
the HMOX2 gene were studied using TaqMan probes. These 4 SNPs that were selected because of their putative 
functional effects and their expected allele frequency in Caucasian individuals4,6. HMOX1 SNP rs2071746 (an 
upstream variant), HMOX1 rs2071747 (a missense mutation within the exon 1 of the HMOX1 gene), the SNP 
rs2270363 (a polymorphism in the regulatory region of the human HMOX2 gene), and rs1051308 (a polymor-
phism in the 3′ untranslated region).
Genotyping, which was performed in genomic DNA from venous blood samples of participants, was carried 
out using TaqMan assays (Life Technologies, Alcobendas, Madrid, Spain) designed to detect the four previously 
mentioned SNPs designated respectively by the supplier with the following part numbers: C__15869717_10, 
Relapsing-remitting 
MS No (%; 95% CI)
Secondary 
progressive No (%; 
95% CI)
Primary progressive 
No (%; 95% CI)
GENOTYPES
HMOX1 rs2071746 A/A 55 (35.0; 27.6–42.5) 29 (31.2; 21.8–40.6) 18 (42.9; 27.9–57.8)
A/T 74 (47.1; 39.3–54.9) 47 (50.5; 40.4–60.7) 18 (42.9; 27.9–57.8)
T/T 28 (17.8; 11.8–23.8) 17 (18.3; 10.4–26.1) 6 (14.3; 3.7–24.9)
HMOX1 rs2071747 G/G 145 (92.4; 88.2–96.5) 85 (91.4; 85.7–97.1) 36 (85.7; 75.1–96.3)
G/C 11 (7.0; 3.0–11.0) 8 (8.6; 2.9–14.3) 6 (14.3; 3.7–24.9)
C/C 1 (0.6; 0.-6-1.9) 0 (0.0; 0.0-0.0) 0 (0.0; 0.0-0.0)
HMOX2 rs2270363 G/G 70 (44.6; 36.8–52.4) 43 (46.2; 36.1–56.4) 14 (33.3; 19.1–47.6)
G/A 65 (41.4; 33.7–49.1) 39 (41.9; 31.9–52.0) 26 (61.9; 47.2–76.6)
A/A 22 (14.0; 8.6–19.4) 11 (11.8; 5.3–18.4) 2 (4.8; -1.-7-11.2)
HMOX 2 rs1051308 A/A 78 (49.7; 41.9–57.5) 48 (51.6; 41.5–61.8) 21 (50.0; 34.9–65.1)
A/G 64 (40.8; 33.1–48.5) 36 (38.7; 28.8–48.6) 20 (47.6; 32.5–62.7)
G/G 15 (9.6; 5.0–14.2) 9 (9.7; 3.7–15.7) 1 (2.4; -2.-2-7.0)
ALLELES
HMOX1 rs2071746 A 184 (58.6; 53.2–64.0) 105 (56.5; 49.3–63.6) 54 (64.3; 54.0–74.5)
T 130 (41.4; 36.0–46.8) 81 (43.5; 36.4–50.7) 30 (35.7; 25.5–46.0)
HMOX1 rs2071747 G 301 (95.9; 93.7–98.1) 178 (95.7; 92.8–98.6) 78 (92.9; 87.3–98.4)
C 13 (4.1; 1.9–6.3) 8 (4.3; 1.4–7.2) 6 (7.1; 1.6–12.7)
HMOX2 rs2270363 G 205 (65.3; 60.0–70.6) 125 (67.2; 60.5–74.0) 54 (64.3; 54.0–74.5)
A 109 (34.7; 29.4–40.0) 61 (32.8; 26.0–39.5) 30 (35.7; 25.5–46.0)
HMOX 2 rs1051308 A 220 (70.1; 65.0–75.1) 132 (71.0; 64.4–77.5) 62 (73.8; 64.4–83.2)
G 94 (29.9; 24.9–35.0) 54 (29.0; 22.5–35.6) 22 (26.2; 16.8–35.6)
Table 3.  HMOX genotypes and allelic variants of patients with MS according with the evolutive type of MS. 
The values in each cell represent: number (percentage; 95% confidence intervals). None of the subgroups of MS 
patients displayed statistically significant differences as compared to control individuals.
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C__22272778_10, C__15957370_10 and C___9695078_1_. An Eppendorf realplex thermocycler, using fluores-
cent probes, was used for the detection by qPCR. The amplification conditions were the following: after a dena-
turation time of 10 min at 96 °C, 45 cycles of 92 °C 15 sec and 60 °C 90 sec were carried out and fluorescence was 
measured at the end of each cycle and at endpoint. Determinations were done by triplicate in all samples, and then 
genotypes were assigned both using a gene identification software (RealPlex 2.0, Eppendorf) and analysing the 
reference cycle number for each fluorescence curve, calculated by means of the CalQPlex algorithm (Eppendorf).
Copy number variations (CNVs) of the HMOX1 and HMOX2 genes were analyzed using the TaqMan copy 
number assays Hs00774483_cn and Hs01223070_cn, respectively. Both assays were designed to hybridize within 
the open reading frame in the target genes (Life Technologies, Alcobendas, Madrid, Spain). Amplification was 
carried out in an Applied Biosystems 7500 real-time thermocycler as described by the manufacturer, using as a 
copy number reference assay RNAse P. All reactions were carried out in quadruplicate. Results were analyzed 
by means of the CopyCaller Software (Life Technologies, Alcobendas, Madrid, Spain). According to standard 
procedures in CNV analyses, we designed as heterozygous (null/present) those samples with a single copy of the 
corresponding gene. Since the probes were designed to detect exonic sequences, even if the rest of the gene would 
remain in these so called null alleles, the translated protein would not be functional.
Statistical analysis. The DeFinetti program (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl), the PLINK software31, 
and the program PHASE v2.1.132 were used, respectively, to analyze the Hardy-Weinberg equilibrium, to perform 
the allelic and genotype analyses, and to perform haplotype reconstruction using the default model for recom-
bination rate variation with 1000 iterations, 500 burn-in iterations, and a thinning interval of 1. Diplotypes were 
obtained from the combination of haplotypes in the best run (the one that showed the maximum consistency of 
results across all runs33 Statistical analyses were performed using the SPSS 19.0 for Windows (SPSS Inc., Chicago, 
Illinois, USA). We calculated intergroup comparison values by means of the χ 2 or Fisher tests when appropriate, 
and calculated the 95% confidence intervals as well. We used the False discovery rate procedure34 to calculate 
correction for multiple testing (Pc values).
The determination of the sample size was done from variant allele frequencies observed in control individuals 
with a genetic model analyzing the frequency for carriers of the disease gene with a RR value = 1.5 (p = 0.05). 
The statistical power for two-tailed associations for the presence of the SNPs identified in this study (rs2071746, 
rs2071747, rs2270363 and rs1051308) was 97.6%, 43.1%, 96.3% and 97.0%. Testing for heterogeneous association 
(homogeneity test) was analyzed by using the Breslow–Day test.
The negative predictive value (NPV) was calculated as d/r2 (d = number of control individuals with the risk 
factor absent; r2 = sum of patients and controls with the risk factor absent)35.
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